Venture
Generalist, opportunistic early-stage investing and strategic advisory — from AI, fintech, and B2B SaaS to edtech, medtech, robotics, agtech, consumer, and media.
40+
Portfolio Companies
10+
Years Investing
$10B+
Portfolio Valuations
Seed — A
Investment Stage
HopperExited
Paper
ICON
Potloc
Cision Vision
Vetster
Gradient Health
Soundskrit
Prevu3D
Data Sentinel
CalliaExited
Nudge
Calabrio
Hello Darwin
BuyBack Booth
Tab Commerce
ForceN
Out of the Box
Waitwell
PicketaExited
DrugBankExited
Lexop
CloverBloomberg
Travel App Hopper Eyes Long-Term IPO Plan, $10 Billion Valuation
One of Canada's largest private tech companies, Montréal-founded Hopper is targeting a public listing that could value the business at up to $10 billion.
Read Article →
Bloomberg
Thoma Bravo Buys Verint in $2B Deal to Merge With Calabrio
Thoma Bravo took Verint private to combine it with Calabrio, creating an AI-powered customer-experience platform serving a $50B+ market.
Read Article →
MIT Koch Institute
Cancer Moonshot Boosts Cision Vision With Award of Up to $22.3M
Cision Vision was the only medtech prime awardee in ARPA-H's $150M Precision Surgical Interventions program, advancing dye-free infrared imaging for surgery.
Read Article →
BetaKit
Loan Collection Platform Eltropy Acquires Montréal's Lexop
California fintech Eltropy acquired Lexop, folding its people-first repayment technology into an AI communications platform for credit unions and banks.
Read Article →
BetaKit
Picketa Raises $2.1M to Help Farmers Make the Most of Their Fertilizer
The agtech startup is scaling its LENS real-time leaf-tissue analysis platform, cutting growers' in-season fertilizer spend by up to 20 percent.
Read Article →
01
Industry Agnostic
We welcome every idea with the potential to make a positive impact. Our diverse portfolio achieves high returns with careful attention to various economic cycles.
02
Investment Horizon
Our long-term horizon provides flexibility and allows us to maximize the value of our investments while protecting the best interests of our companies.
03
Growth Oriented
We exclusively target high-growth opportunities with asymmetric upside potential, leveraging our network's inbound deal-flow alongside outbound research.
04
Team Focused
The mark of a promising early-stage company is a resilient, intelligent, and energetic team. Our decisions are guided by the "jockey over the horse" approach.
Strategic advisory to early-stage companies across biotech, Web3, consumer, and infrastructure — supporting capital strategy, investor positioning, governance, and commercial partnerships.